A novel homozygous variant in GPIHBP1: A case series of familial chylomicronemia syndrome from Colombia.

IF 4.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Alejandro Román González, Oriana F Arroyo-Ripoll, Andrés F Garcia-Ramos, Claudia Monsalve, Salomon Daguer, Francisco Barón, Gabriela Berg, Gregorio Fariña, Nora Alejandra Zuluaga, Adriana Carolina Forero, Juan Patricio Nogueira
{"title":"A novel homozygous variant in GPIHBP1: A case series of familial chylomicronemia syndrome from Colombia.","authors":"Alejandro Román González, Oriana F Arroyo-Ripoll, Andrés F Garcia-Ramos, Claudia Monsalve, Salomon Daguer, Francisco Barón, Gabriela Berg, Gregorio Fariña, Nora Alejandra Zuluaga, Adriana Carolina Forero, Juan Patricio Nogueira","doi":"10.1016/j.jacl.2025.06.006","DOIUrl":null,"url":null,"abstract":"<p><p>Familial chylomicronemia syndrome (FCS) is a rare monogenic disorder characterized by severe hypertriglyceridemia caused by pathogenic variants in genes involved in triglyceride metabolism. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) plays a critical role in the lipolytic processing of triglyceride-rich lipoproteins. We present three unrelated cases of FCS with a newly identified homozygous complex insertion-deletion variant in GPIHBP1, namely c.460_461delinsAAA, p.Ala154Lysfs*153. All three cases presented with severe hypertriglyceridemia, a high FCS clinical score, and significantly reduced LPL activity (being 6.6 mUI the value corresponding to 20% of normal activity). These observations expand the spectrum of pathogenic GPIHBP1 variants in FCS. The identification of GPIHBP1 variant reinforces the causal link between GPIHBP1 mutations and LPL deficiency, as evidenced by diminished LPL activity, and further expands the genetic landscape of FCS. All three cases presented with severe hypertriglyceridemia, a high FCS clinical score and significantly reduced LPL activity (being 6.6 mUI the value corresponding to 20% of normal activity). These observations expand the spectrum of pathogenic GPIHBP1 variants in FCS.</p>","PeriodicalId":15392,"journal":{"name":"Journal of clinical lipidology","volume":" ","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical lipidology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jacl.2025.06.006","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Familial chylomicronemia syndrome (FCS) is a rare monogenic disorder characterized by severe hypertriglyceridemia caused by pathogenic variants in genes involved in triglyceride metabolism. Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 (GPIHBP1) plays a critical role in the lipolytic processing of triglyceride-rich lipoproteins. We present three unrelated cases of FCS with a newly identified homozygous complex insertion-deletion variant in GPIHBP1, namely c.460_461delinsAAA, p.Ala154Lysfs*153. All three cases presented with severe hypertriglyceridemia, a high FCS clinical score, and significantly reduced LPL activity (being 6.6 mUI the value corresponding to 20% of normal activity). These observations expand the spectrum of pathogenic GPIHBP1 variants in FCS. The identification of GPIHBP1 variant reinforces the causal link between GPIHBP1 mutations and LPL deficiency, as evidenced by diminished LPL activity, and further expands the genetic landscape of FCS. All three cases presented with severe hypertriglyceridemia, a high FCS clinical score and significantly reduced LPL activity (being 6.6 mUI the value corresponding to 20% of normal activity). These observations expand the spectrum of pathogenic GPIHBP1 variants in FCS.

一种新的GPIHBP1纯合变异:来自哥伦比亚的家族性乳糜微粒血症综合征病例系列。
家族性乳糜低血症综合征(FCS)是一种罕见的单基因疾病,其特征是由甘油三酯代谢相关基因的致病性变异引起的严重高甘油三酯血症。糖基磷脂酰肌醇锚定的高密度脂蛋白结合蛋白1 (GPIHBP1)在富含甘油三酯的脂蛋白的脂溶过程中起关键作用。我们报告了三个不相关的FCS病例,其中GPIHBP1中有一个新发现的纯合复合体插入-缺失变体,即c.460_461delinsAAA, p.Ala154Lysfs*153。所有3例患者均出现严重的高甘油三酯血症,FCS临床评分较高,LPL活性显著降低(为6.6 mUI,相当于正常活动的20%)。这些观察结果扩大了FCS中致病性GPIHBP1变异的范围。GPIHBP1变异的鉴定强化了GPIHBP1突变与LPL缺陷之间的因果关系,LPL活性降低证明了这一点,并进一步扩大了FCS的遗传格局。所有3例患者均表现为严重的高甘油三酯血症,FCS临床评分高,LPL活性显著降低(6.6 mUI,相当于正常活动的20%)。这些观察结果扩大了FCS中致病性GPIHBP1变异的范围。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.00
自引率
6.80%
发文量
209
审稿时长
49 days
期刊介绍: Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. Sections of Journal of clinical lipidology will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信